Benjamin Shepherd is a recognized exchange-traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, including their managers and strategies. Ben looks for investments that have proven themselves in both bull and bear markets. Ben also specializes in covering emerging markets, pinpointing the most dynamic investments in developing nations for market-beating growth.
Ben is chief investment strategist of Global Investment Strategist, which examines top-performing investments in Brazil, Russia, India, China, Japan, Indonesia, South Korea, and other rising economic powers. He’s also chief investment strategist of Benjamin Shepherd’s Wall Street, born from his years learning from famed investment guru Louis Rukeyser and subsequently serving as editor of Louis Rukeyser’s Wall Street and Louis Rukeyser’s Mutual Funds. In July 2013 Ben launched the Inflation Survival Letter, which guides investors on positioning themselves now for inflation’s inevitable arrival.
Along with these duties, Ben finds time to regularly contribute to Personal Finance, Investing Daily’s flagship product.
Did you miss the first Coca-Cola? The first McDonalds? Apple’s IPO? Here’s your second chance. From Eastern Europe to the Pacific Rim to South America – new markets are buoying investor profits. These are multiple market opportunities – new industrial giants, pharmaceuticals, and high-tech. Plus moneyed new consumers with any eye to buy every gadget – from phones to refrigerators – that have long been staples in our own society. For investors, it’s a once-in-a-lifetime ground-floor opportunity to profit from the birth of new economies. Learn More
Don’t let your wealth erode – lock in investments that will thrive as inflation spirals up! Learn More
Here’s why the latest employment statistics point to accelerating inflation.
Here’s why prudent investors should steer clear of Putin’s Russia.
This biotech is turning America’s passion for pets into profits.
Brazil’s government is making prudent economic policy moves that should benefit the entire region.
This beaten down biotech boasts under-appreciated future promise.
The failed attempt to limit cost-of-living increases for retirees would have cost the too much for too many Americans.
As shadow banking in the country gets out of hand, the Middle Kingdom is seeking to add rationality to its lending policies.
Investors in Big Pharma shouldn’t overreact to impending patent expirations.
The beleaguered emerging markets are poised for a rebound. Here’s how to play the trend.
As hedges against inflation, asset-heavy companies can be a double-edged sword.